These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment. van der Horst HJ; de Jonge AV; Hiemstra IH; Gelderloos AT; Berry DRAI; Hijmering NJ; van Essen HF; de Jong D; Chamuleau MED; Zweegman S; Breij ECW; Roemer MGM; Mutis T Blood Cancer J; 2021 Feb; 11(2):38. PubMed ID: 33602901 [TBL] [Abstract][Full Text] [Related]
5. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Plosker GL; Figgitt DP Drugs; 2003; 63(8):803-43. PubMed ID: 12662126 [TBL] [Abstract][Full Text] [Related]
6. CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells. Martens AWJ; Janssen SR; Derks IAM; Adams Iii HC; Izhak L; van Kampen R; Tonino SH; Eldering E; van der Windt GJW; Kater AP J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581054 [TBL] [Abstract][Full Text] [Related]
7. A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era. Robinson HR; Qi J; Cook EM; Nichols C; Dadashian EL; Underbayev C; Herman SEM; Saba NS; Keyvanfar K; Sun C; Ahn IE; Baskar S; Rader C; Wiestner A Blood; 2018 Aug; 132(5):521-532. PubMed ID: 29743179 [TBL] [Abstract][Full Text] [Related]
8. Approved and emerging Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia. Hatashima A; Karami M; Shadman M Expert Opin Pharmacother; 2022 Sep; 23(13):1545-1557. PubMed ID: 35973973 [TBL] [Abstract][Full Text] [Related]
9. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial. Thieblemont C; Phillips T; Ghesquieres H; Cheah CY; Clausen MR; Cunningham D; Do YR; Feldman T; Gasiorowski R; Jurczak W; Kim TM; Lewis DJ; van der Poel M; Poon ML; Cota Stirner M; Kilavuz N; Chiu C; Chen M; Sacchi M; Elliott B; Ahmadi T; Hutchings M; Lugtenburg PJ J Clin Oncol; 2023 Apr; 41(12):2238-2247. PubMed ID: 36548927 [TBL] [Abstract][Full Text] [Related]
10. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia. Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464 [TBL] [Abstract][Full Text] [Related]
11. Frontline Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Targeted Therapy vs. Chemoimmunotherapy. Small S; Ma S Curr Hematol Malig Rep; 2021 Aug; 16(4):325-335. PubMed ID: 34021874 [TBL] [Abstract][Full Text] [Related]
12. BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax. Lin VS; Lew TE; Handunnetti SM; Blombery P; Nguyen T; Westerman DA; Kuss BJ; Tam CS; Roberts AW; Seymour JF; Anderson MA Blood; 2020 Jun; 135(25):2266-2270. PubMed ID: 32244251 [TBL] [Abstract][Full Text] [Related]
13. Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Review. Shadman M JAMA; 2023 Mar; 329(11):918-932. PubMed ID: 36943212 [TBL] [Abstract][Full Text] [Related]
14. Update on the management of relapsed/refractory chronic lymphocytic leukemia. Bennett R; Seymour JF Blood Cancer J; 2024 Feb; 14(1):33. PubMed ID: 38378673 [TBL] [Abstract][Full Text] [Related]
15. Targeting Bruton's Tyrosine Kinase in CLL. Ahn IE; Brown JR Front Immunol; 2021; 12():687458. PubMed ID: 34248972 [TBL] [Abstract][Full Text] [Related]
17. Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels. Stanglmaier M; Faltin M; Ruf P; Bodenhausen A; Schröder P; Lindhofer H Int J Cancer; 2008 Sep; 123(5):1181-9. PubMed ID: 18546289 [TBL] [Abstract][Full Text] [Related]
18. Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax. Gángó A; Kiss R; Farkas P; Hanna E; Demeter J; Deák B; Lévai D; Kotmayer L; Alpár D; Matolcsy A; Bödör C; Mátrai Z; Timár B Pathology; 2022 Feb; 54(1):95-103. PubMed ID: 34332791 [TBL] [Abstract][Full Text] [Related]
19. New Treatment Options for Newly-Diagnosed and Relapsed Chronic Lymphocytic Leukemia. Iskierka-Jażdżewska E; Obracaj A; Urbaniak M; Robak T Curr Treat Options Oncol; 2022 Jun; 23(6):775-795. PubMed ID: 35357653 [TBL] [Abstract][Full Text] [Related]
20. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. Engelberts PJ; Hiemstra IH; de Jong B; Schuurhuis DH; Meesters J; Beltran Hernandez I; Oostindie SC; Neijssen J; van den Brink EN; Horbach GJ; Verploegen S; Labrijn AF; Salcedo T; Schuurman J; Parren PWHI; Breij ECW EBioMedicine; 2020 Feb; 52():102625. PubMed ID: 31981978 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]